特别引人关注的是，全球生物药物巨头吉利德（Gilead）首次在中国隆重推出了针对“隐形杀手”——原发性胆汁性胆管炎（PBC）的新药Seladelpar，以及革命性HIV长效治疗药物Lenacapavir。 背景：肝脏的隐形杀手 原发性胆汁性胆管炎（PBC）是一种慢性自身免疫性疾病 ...

吉利德创新药物Seladelpar也在本届进博会上迎来中国“首秀”。该药物已于2024年8月获得美国食品药品监督管理局（FDA）加速审批，为原发性胆汁性胆管炎患者的二线治疗带来了全新选择。作为一种慢性自身免疫性肝内胆汁淤积性疾病，原发性胆汁性胆管炎（ ...

医师报讯 ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

11月5日，第七届中国国际进口博览会开幕首日，全球领先的生物制药企业吉利德科学展台正式揭幕。围绕“创造一个更健康的世界”这一主题，吉利德在500平方米展台上全方位展现公司在病毒学、肿瘤学、真菌学三大核心领域的革新疗法及研发进展，集中展示通过创新合作提升健康公平可及的主要成果，再次彰显其深耕中国市场、服务国内患者、加强共赢合作的坚定决心。

吉利德公司称艾滋病口服治疗研究取得积极成果，研究涉及islatravir和lenacapavir的联合治疗方案。 吉利德（Gilead）与默沙东（Merck & Co）此前宣布启动 ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

(GILD) Wednesday said it has signed royalty-free licensing agreements with six pharmaceutical manufacturers to manufacture and supply generic versions of the company's HIV drug lenacapavir ...

US pharma company Gilead Sciences is seeking regulatory approval for the drug lenacapavir in a number of African countries – a key step towards making it available across the region, where ...

Kisii — The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...